WO2006030737A1 - 動脈閉塞性疾病モデル動物の作製 - Google Patents
動脈閉塞性疾病モデル動物の作製 Download PDFInfo
- Publication number
- WO2006030737A1 WO2006030737A1 PCT/JP2005/016756 JP2005016756W WO2006030737A1 WO 2006030737 A1 WO2006030737 A1 WO 2006030737A1 JP 2005016756 W JP2005016756 W JP 2005016756W WO 2006030737 A1 WO2006030737 A1 WO 2006030737A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- artery
- autologous blood
- arterial
- blood clot
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B23/00—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes
- G09B23/28—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes for medicine
- G09B23/30—Anatomical models
- G09B23/306—Anatomical models comprising real biological tissue
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/486—Diagnostic techniques involving generating temporal series of image data
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
- A61B6/504—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of blood vessels, e.g. by angiography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
- A61B6/507—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for determination of haemodynamic parameters, e.g. perfusion CT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
- A61B6/508—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for non-human patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/106—Primate
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
Definitions
- the present invention relates to a method for producing an arterial occlusive disease model animal, a kit or system therefor, and an arterial embolized animal model obtained by the method or the system.
- a method for producing a non-human arterial occlusive disease model animal characterized by occluding an artery by ligation at a specific site or an autologous blood clot, and a kit or system therefor and the method or the system It relates to an arterial embolization animal model obtained by
- heart disease models such as myocardial infarction have been frequently used in medical research such as cardiovascular system and organ transplantation, or drug development for cardiovascular disease.
- these heart disease models have been used for regenerative medicine research.
- a coronary artery ligation method by thoracotomy is generally used, but the conventional ligation method causes fibrillation immediately after the treatment. The probability of death is extremely high. For this reason, a model preparation method using an ameloid ring (a means of slowly occluding a blood vessel in about two weeks) is widely used.
- the major problem with this method is that the degree of occlusion varies, non-infarct cases and incomplete infarct cases occur, and a stable pathologic model is lacking.
- Another problem is that the fatality rate is relatively high in a relatively short period of time (for example, one month after treatment).
- the conventional vascular embolization method has a drawback in that the reliability of vascular embolism and the degree of ischemia after embolization are varied, and there is a lack of quantitativeness. .
- the invasiveness to animals is great, and the damage to animals is great. was there. If an animal model that overcomes these disadvantages is obtained, research on diseases and disorders will progress through arterial embolization including stroke, and it will also lead to the discovery of new treatments for these.
- animal models that have overcome these disadvantages are considered to be very useful for the development of new drugs and regenerative medicine research for the treatment and prevention of diseases and disorders caused by arterial embolization.
- Non-Patent Literature l Hudgins WR et al., Stroke. 1970 Mar- Apr; l (2): 107-11
- Non-Patent Document 2 Watanabe 0 et al., Stroke 8: 61—70, 1975
- Non-Patent Document 3 Kito G et al., J Neurosci Methods. 2001 Jan 30; 105 (1): 45-53
- the present inventors ligated a blood vessel downstream from the artery site to be occluded, and then reached the artery to be completely occluded at the site to be occluded. It was found that a stable myocardial infarction model can be obtained.
- the present inventors use a cerebral angiography device to select an autologous blood clot coagulated with a coagulant into an artery to form an embolus, thereby selecting a desired site in the artery. It was found that an arterial embolic animal model can be obtained which can be obstructed by a blood clot and can solve the above problems. [0011] That is, the present invention provides:
- a myocardial infarction animal model is characterized by ligating a blood vessel downstream of an arterial site of a heart to be occluded, and then occlusion of the artery at the site to be occluded.
- the method according to (1) which is obtained;
- an arterial occlusion means and an arterial ligation means as essential, and a kit for preparing a myocardial infarction animal model used in the method according to any one of (2) to (4);
- the present invention further provides:
- a coagulant is added to autologous blood collected from animals other than humans to produce an autologous blood clot, and then the autologous blood clot is delivered to the intended arterial lumen,
- the method according to (1) wherein an angiographic device is used to deliver an autologous blood clot to an arterial lumen, and an arterial embolization animal model is obtained;
- the present invention provides a method for producing a myocardial infarction model that can completely occlude the main artery and that can provide a stable disease state with a low lethality of animals, and a kit therefor. Furthermore, according to the present invention, there is provided a method for preparing a vascular embolized animal model that can be quantitatively analyzed with a high degree of certainty of vascular embolism and little variation. When the method of the present invention is used, the damage to animals that are less invasive to animals can be reduced.
- FIG. 1 is a treatment site (left panel) by the method of the present invention and a photograph (right panel) showing an infarct state of an individual's myocardium.
- the arrow A on the left panel indicates the site where the armoroid ring was attached, the arrow B indicates the ligation site, and a section was cut out on a plane perpendicular to the paper surface including the diagonal lines. Fibrosis is seen in the part indicated by the ring on the right panel.
- the upper right panel is a photograph showing the appearance of the heart after treatment, and the lower right panel is a photograph showing a heart section every lcm.
- FIG. 2 is a graph showing the number of animals alive (upper panel) and survival rate (lower panel) up to one month after treatment in the method of the present invention and the conventional method.
- Figure 3 shows a comparison of blood clots at 24 hours after blood collection (left panel, upper part is control, middle part is ADP supplemented system, lower part is thrombin supplemented system) and blood clot.
- a normal photograph (top right panel) and an X-ray photograph (bottom right panel) of a soaked povidone solution are shown.
- FIG. 4 is a cerebral blood vessel X-ray image before occlusion (left panel) and immediately after left middle cerebral artery occlusion with an autologous blood clot (right panel).
- FIG. 5 is a PET image showing temporal changes in cerebral blood flow (upper stage), oxygen uptake rate (middle stage), and oxygen metabolism (lower stage) after occlusion. From left, images are shown 15, 30, 60, 120, 180 minutes after occlusion.
- the present invention provides, in one embodiment, a method for producing a non-human arterial occlusive disease model animal, wherein the artery is occluded by ligation at a specific site or an autologous blood clot. .
- the present invention relates to a method of ligating a blood vessel downstream of an arterial site of a heart to be occluded in a laboratory animal other than a human, and then occlusion of the artery at the site to be occluded.
- a method for producing a myocardial infarction animal model is provided.
- the animal used in the present invention is an experimental animal (excluding humans, it is a matter of course)! /, A force that can be applied to any experimental species S, and an experimental animal is appropriately selected. be able to.
- experimental animals include pigs, rats, mice, rabbits, guinea pigs, dogs, cats, monkeys, rabbits, horses, and hidges.
- the present invention is useful for pigs that have been widely used in recent years and are particularly poor in collateral blood vessels.
- Pigs 1) have physiological and anatomical findings; 2) phagocytosis, physiology related to digestion and absorption; and 3) characteristics of coronary artery distribution, arterial endothelial structure, etc.
- the viewpoint power of animal welfare is also an animal suitable for the present invention.
- minipigs have a clear genetic background and are particularly suitable for the present invention.
- the organ to which the method and kit of the present invention are applied is the heart.
- occlusion means an occlusion rate force measured by the method described in the examples, usually about 80% or more, preferably about 90% or more.
- the arterial site to be occluded may be! Or a site of deviation, and may be appropriately selected according to factors such as the position, size, degree, and type of animal used. it can.
- the arterial site to be occluded is the anterior descending branch just below the bifurcation of the left coronary artery.
- the method for producing a myocardial infarction model of the present invention includes two steps. First, a blood vessel downstream of an arterial site of the heart to be occluded is ligated using an arterial ligation means. Ligation should be done completely. It is important to make the entire myocardium resistant to ischemia by performing such local ligation. As a means for ligating arteries, a force represented by a suture is used. Other means such as a clip can also be used. The clip is preferably a small metal one.
- the ligation site is on the distal side of the artery to be occluded and is fine even after complete ligation.
- the artery site to be occluded is occluded using a means for occlusion of the artery after a certain time. In other words, the entire myocardium is established with resistance to ischemia and is closed. In general, occlusion of the artery to be occluded is performed approximately 30 minutes after ligation. In the method of the present invention, when a cameloid ring is used for occlusion as described later, it takes about 2 weeks until ligation and complete occlusion occur. The occlusion rate 24 hours after the occlusion procedure reaches approximately 60-70%, depending on the wall thickness.
- the artery site to be occluded is occluded by using an arterial occlusion means.
- an arterial occlusion means for example, it is preferable to prevent blood vessel snoring by applying xylocaine jelly to the blood vessel.
- the arterial occlusion means a gameloid ring is typical, but any other means may be used as long as it is a means for slowly closing the blood vessel over time to cause occlusion.
- the chest is closed and the procedure is terminated. Closure can be performed according to conventional methods.
- the present invention also provides a myocardial infarction model preparation kit for use in the above myocardial infarction model preparation method.
- the kit essentially includes arterial occlusion means and arterial ligation means.
- instructions for carrying out the method for preparing a myocardial infarction model of the present invention are attached to the kit.
- the myocardial infarction animal model obtained by the above method or kit of the present invention has a stable disease state, medical research such as cardiovascular system, organ transplantation or regenerative medicine, or drug development for cardiovascular disease. It is very useful in etc.
- the present invention provides that an autologous blood clot obtained by adding a coagulant is delivered into an artery to form an embolus, and at the time of the delivery.
- the present invention provides a method for producing a non-human arterial embolized animal model, characterized by using an angiographic apparatus.
- the animal used in the method of the present invention may be any mammal other than humans.
- rodents rats, mice, etc.
- primates rhesus monkeys, Chimpanzees
- dogs, cats, pigs and the like are preferable animals.
- the present invention can be applied to any artery of an animal.
- this The light method is applied to brain or heart arteries.
- the method of the present invention comprises two steps.
- the first step is the production of autologous blood clot.
- the blood of the target animal is also collected in advance, mixed with a coagulant, and then incubated for a certain time to obtain a thrombus in a sufficiently solidified state.
- Blood collection from animals can be performed according to conventional methods. For example, in the case of rodent animals, the caudal artery force can also be collected. The amount of blood collected can be appropriately selected according to the type of animal and the purpose of treatment.
- the shape of the autologous blood clot to be delivered is preferably a long axis shape with respect to the blood vessel.
- the autologous blood clot becomes a shape that conforms to the shape and running property of the blood vessel, and can flow to the periphery of the blood vessel or immediately create a thrombus in a wide blood vessel region.
- an autologous blood clot having a long axis shape for example, when autologous blood is mixed with a coagulant and incubated, it is filled into a container that is thinner than the inner diameter of the catheter used for the treatment, for example, an appropriate tube. Incubate.
- the incubation container may be made of a material that does not adversely affect blood coagulation, for example, polyethylene.
- Incubation time and temperature should be selected to ensure sufficient solidification, but will depend on the type of animal, autologous blood state, desired thrombus characteristics, type and location of the artery where the embolus should occur, the degree of the desired disease, etc. It can be changed as appropriate. In general, incubate at a temperature near the body temperature of the target animal for about 1 day. These incubation conditions and equipment can be easily changed'selected by those skilled in the art.
- the term “coagulant” refers to a drug that coagulates autologous blood to a degree sufficient to cause a desired embolism, and various types are known.
- Examples include ADP (adenosine diphosphate) having a platelet aggregation effect, thrombin that promotes fibrin formation and thrombus formation.
- the type and concentration of the coagulant can be appropriately selected and determined by those skilled in the art according to the purpose. For example, 30 ⁇ gZml !, 100 ⁇ gZml ADP and 0.5% (w / v), and 10% (w / v) thrombin in a microwave oven or incubator at 37 ° C for 24 hours.
- the autologous blood may be coagulated by keeping it at a high level.
- the second step of the method of the present invention is a step of delivering an autologous blood clot prepared as described above to a desired blood vessel site to form an embolus.
- the means for delivering the autologous blood clot is not particularly limited, but it is generally performed using a catheter. Using a catheter that matches the inner diameter of the artery to be formed, the catheter can be placed in the target blood vessel by inserting from the placed sheath. Various types of catheters are known, and power angiography catheters that can be appropriately selected and used are preferred. The sheath is generally placed in the femoral artery. When performing catheter placement, it is important to accurately guide the catheter to the desired site by using an angiographic device.
- a thrombus can be smoothly introduced by placing the tip of the tube in advance at the catheter entrance. Whether or not the target blood vessel is blocked by the thrombus can be grasped by a cerebral angiography apparatus, for example, by X-ray cerebral angiography using a contrast medium. If necessary, the remaining thrombus can be confirmed at the time of X-ray cerebral angiography by immersing the prepared thrombus in a solution containing a pharmacological agent in advance.
- the blood flow state such as blood flow, oxygen uptake ability, oxygen metabolism ability, etc. is measured using PET.
- PET Various types of PET apparatuses are currently used, and can be selected and used as appropriate. Measurement items for confirming ischemia can be appropriately selected by those skilled in the art, and methods for measuring these using PET are also known.
- the present invention provides an arterial embolization module for animals other than humans, which essentially comprises an autologous blood clot formation means using a coagulant, a means for delivering the autologous blood clot into an artery, and an angiography apparatus.
- Provide Dell fabrication system The system is used in the method for producing an arterial embolized animal model of the present invention.
- the means for forming an autologous blood clot with a coagulant may include, for example, a coagulant and an incubation container.
- the means for delivering the autologous blood clot into the artery may include, for example, an angiographic catheter.
- the angiography apparatus may be a high resolution X-ray angiography apparatus.
- the system may further include a PET device for confirming the blood flow state after treatment.
- the arterial embolization animal model obtained by the above method or system of the present invention has little variation in the degree of vascular embolism, quantitative analysis is possible. Therefore, the arterial embolized animal model obtained by the present invention is very useful for diseases and disorders caused by arterial embolism, methods for treatment and prevention, new drug development for these diseases, or regenerative medicine research.
- Example 1 Preparation of a porcine chronic myocardial infarction model
- the state of the heart of the animal was examined 3 months after the treatment according to the present invention was performed.
- Significant fibrosis is seen in the apical region of the individual's heart, and there is a smell in the heart section every 1 cm.
- remarkable fibrosis inside the myocardium was observed (Fig. 1 right panel).
- Such fibrosis indicates a certain infarct occurrence.
- the treatment according to the invention showed similar infarcts in the myocardium of all five pigs, indicating the stability 'certainty of the method of the invention.
- the occlusion rate of each individual was 90% or more, and the variation was small.
- the occlusion rate of each individual was 69.8% to 100%, and the variation was large.
- the occlusion rate was calculated according to the following equation by measuring the blood vessel lumen area in front of the ameloid ring and the blood vessel lumen area on the third day after the treatment:
- the disadvantages of the conventional ligation method in which only occlusion with a gameloid ring is carried out are that there are large variations in occlusion, high lethality, unstable pathological conditions. I was able to resolve this problem.
- Example 2 Examination of blood coagulant and coagulation conditions
- the degree of coagulation was examined using ADP and thrombin as blood coagulants.
- the ADP concentration was 30 / ⁇ 8 ⁇ 1, 100 gZml (all without thrombin), and the thrombin concentrations were 0.5% (wZv) and 10% (w / v) (all without ADP).
- Force-Ventral caudal arterial force in monkeys Blood is collected, blood is added to the force tail with or without coagulant, incubated at 37 ° C for 24 hours, and then extruded to coagulate. I observed the situation.
- the control is the addition of no coagulant (coagulated blood only). The results are shown in the left panel of Fig. 3. The higher the ADP concentration, the stronger the coagulation.
- Thrombin In both cases, 0.5% (wZv) and 10% (wZv) were coagulated at the same degree.
- X-rays were taken of a blood clot obtained by incubating 24 hours at 37 ° C with ADP 100 g and thrombin 10%. As shown in the right panel of Fig. 3, a shadow corresponding to the blood clot was observed, and it was found that the position of the blood clot could be confirmed using an X-ray imaging device.
- Example 3 Preparation of an acute brain main artery embolization model
- Male force-quizal monkey (body weight approximately 6 kg) was used as the target animal. Collect a sufficient amount (lml) of blood from the ventral caudal artery of the animal with a syringe containing ADP (final concentration 100 ⁇ g / mL) and thrombin (final concentration 10% (w / v)) as coagulants. Immediately, blood was filled in a polyethylene tube (outer diameter: 0.965 mm, inner diameter: 0.58 mm). When the mixture of blood and coagulant was left in the tube at 37 ° C for 24 hours, a thrombus in a fully solidified state was formed.
- ADP final concentration 100 ⁇ g / mL
- thrombin final concentration 10% (w / v)
- an ultrathin cerebral angiography catheter (3 French) matched to the artery diameter was inserted from the sheath placed in the femoral artery, and the catheter was first placed in the target cerebral blood vessel (left middle cerebral artery).
- a catheter was guided using a high-resolution X-ray brain angiography apparatus (GE Yokogaw a Medical Systems, Mobile C- Arm SERIES 9800 TM) and using a contrast medium (Omnipark 350). After guiding the catheter to the target site, the autologous blood clot prepared as described above was allowed to flow from the catheter.
- PET Siemens, model number: ECAT EXACT 47
- ECAT EXACT 47 The ability to match the left middle cerebral artery region with a decrease in cerebral blood flow. Oxygen metabolism tends to be maintained slightly. I was convinced that I was in a severe ischemic state.
- a desired ischemic state can be created by selectively blocking a blood vessel at a desired site.
- the ischemic state thus created can be quantitatively analyzed and confirmed.
- a method for preparing a myocardial infarction model of the present invention and a kit for the same, and an animal model of myocardial infarction obtained by the method or the kit include research on arterial occlusive diseases, medical research such as organ transplantation, or arterial occlusion. It can be used for drug development for sexually transmitted diseases and for research related to regenerative medicine.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- High Energy & Nuclear Physics (AREA)
- Biophysics (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Radiology & Medical Imaging (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Computational Mathematics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Educational Technology (AREA)
- Educational Administration (AREA)
- Business, Economics & Management (AREA)
- Pure & Applied Mathematics (AREA)
- Mathematical Physics (AREA)
- Mathematical Optimization (AREA)
- Vascular Medicine (AREA)
- Mathematical Analysis (AREA)
- Algebra (AREA)
- Medicinal Chemistry (AREA)
- Animal Husbandry (AREA)
- Theoretical Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
Abstract
Description
Claims
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05781914A EP1808071A4 (en) | 2004-09-13 | 2005-09-12 | CONSTRUCTION OF AN ANIMAL MODEL FOR ARTERIAL CLOSING DISEASE |
| JP2006535873A JP4779122B2 (ja) | 2004-09-13 | 2005-09-12 | 動脈閉塞性疾病モデル動物の作製 |
| US11/662,281 US20080295189A1 (en) | 2004-09-13 | 2005-09-12 | Construction of Arterial Occlusive Disease Animal Model |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004265671 | 2004-09-13 | ||
| JP2004-265677 | 2004-09-13 | ||
| JP2004265677 | 2004-09-13 | ||
| JP2004-265671 | 2004-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2006030737A1 true WO2006030737A1 (ja) | 2006-03-23 |
Family
ID=36059990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2005/016756 Ceased WO2006030737A1 (ja) | 2004-09-13 | 2005-09-12 | 動脈閉塞性疾病モデル動物の作製 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20080295189A1 (ja) |
| EP (1) | EP1808071A4 (ja) |
| JP (1) | JP4779122B2 (ja) |
| WO (1) | WO2006030737A1 (ja) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010150715A1 (ja) | 2009-06-26 | 2010-12-29 | 日本合成化学工業株式会社 | 心筋梗塞非ヒト動物モデル及びその作製方法 |
| JP2011097850A (ja) * | 2009-11-04 | 2011-05-19 | Terumo Corp | 心筋梗塞モデル動物の作製方法 |
| JP2017131158A (ja) * | 2016-01-28 | 2017-08-03 | 中島 博 | 心臓の肉眼観察可能なモデル動物及びその作製方法 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102402650B1 (ko) * | 2020-03-20 | 2022-05-26 | 포항공과대학교 산학협력단 | 3차원 바이오 프린팅 폐색기를 이용한 허혈성 심질환 동물 모델 및 이의 제조방법 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1321032B1 (en) * | 2000-09-27 | 2010-03-17 | Takeda Pharmaceutical Company Limited | Method of constructing heart failure model animal |
| CA2450376A1 (en) * | 2001-04-20 | 2002-10-31 | The Board Of Regents Of The University Of Oklahoma | Cardiac neuromodulation and methods of using same |
-
2005
- 2005-09-12 US US11/662,281 patent/US20080295189A1/en not_active Abandoned
- 2005-09-12 JP JP2006535873A patent/JP4779122B2/ja not_active Expired - Lifetime
- 2005-09-12 EP EP05781914A patent/EP1808071A4/en not_active Withdrawn
- 2005-09-12 WO PCT/JP2005/016756 patent/WO2006030737A1/ja not_active Ceased
Non-Patent Citations (36)
| Title |
|---|
| ANVERSA P; LERI A; KAJSTURA J: "Cardiac regeneration", J AM CALL CARDIOL., vol. 47, 2006, pages 1769 - 1776 |
| BALADY GJ; JETTE D; SCHEER J; DOWNING J: "Changes in exercise capacity following cardiac rehabilitation in patients stratified according to age and gender. Results of the Massachusetts Association of Cardiovascular and Pulmonary Rehabilitation Multicenter Database", J CARDIOPULM REHABIL., vol. 16, 1996, pages 38 - 46 |
| CANTY JM, JR.; SUZUKI G; BANAS MD; VERHEYEN F; BORGERS M; FALLAVOLLITA JA: "Hibernating myocardium: chronically adapted to ischemia but vulnerable to sudden death", CIRC RES., vol. 94, 2004, pages 1142 - 1149 |
| CHEN PS; CHEN LS; CAO JM; SHARIFI B; KARAGUEUZIAN HS; FISHBEIN MC: "Sympathetic nerve sprouting, electrical remodeling and the mechanisms of sudden cardiac death", CARDIOVASC RES., vol. 50, 2001, pages 409 - 416 |
| DE SILVA R; YAMAMOTO Y; RHODES CG; LIDA H; NIHOYANNOPOULOS P; DAVIES GJ; LAMMERTSMA AA; JONES T; MASERI A: "Preoperative prediction of the outcome of coronary revascularization using positron emission tomography", CIRCULATION, vol. 86, 1992, pages 1738 - 1742 |
| DEFRONZO RA; TOBIN JD; ANDRES R: "Glucose clamp technique: a method for quantifying insulin secretion and resistance", AM J PHYSIOL., vol. 237, 1979, pages E214 - 223 |
| FALLAVOLLITA JA; CANTY JM, JR.: "Differential 18F-2-deoxyglucose uptake in viable dysfunctional myocardium with normal resting perfusion: evidence for chronic stunning in pigs", CIRCULATION, vol. 99, 1999, pages 2798 - 2805 |
| FALLAVOLLITA JA; CANTY JM, JR.: "Ischemic cardiomyopathy in pigs with two- vessel occlusion and viable, chronically dysfunctional myocardium", AM J PHYSIOL HEART CIRC PHYSIOL., vol. 282, 2002, pages H1370 - 1379 |
| FALLAVOLLITA JA; LOGUE M; CANTY JM, JR.: "Stability of hibernating myocardium in pigs with a chronic left anterior descending coronary artery stenosis: absence of progressive fibrosis in the setting of stable reductions in flow, function and coronary flow reserve", J AM CO// CARDIOL., vol. 37, 2001, pages 1989 - 1995 |
| FALLAVOLLITA JA; RIEGEL BJ; SUZUKI G; VALETI U; CANTY JM, JR.: "Mechanism of sudden cardiac death in pigs with viable chronically dysfunctional myocardium and ischemic cardiomyopathy", AM J PHYSIOL HEART CIRC PHYSIOL., vol. 289, 2005, pages H2688 - 2696 |
| GHEERAERT PJ; HENRIQUES JP; DE BUYZERE ML; DE PAUW M; TAEYMANS Y; ZIJLSTRA F: "Preinfarction angina protects against out-of-hospital ventricular fibrillation in patients with acute occlusion of the left coronary artery", J AM COLL CARDIOL., vol. 38, 2001, pages 1369 - 1374 |
| HARADA K. ET AL: "Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts", J.CLIN.INVEST., vol. 94, 1994, pages 623 - 630, XP002043081 * |
| KAWAMOTO A. ET AL: "Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia", CIRCULATION, vol. 107, 2003, pages 461 - 468, XP002999855 * |
| KHARBANDA RK; MORTENSEN UM; WHITE PA; KRISTIANSEN SB; SCHMIDT MR; HOSCHTITZKY JA; VOGEL M; SORENSEN K; REDINGTON AN; MACALLISTER R: "Transient limb ischemia induces remote ischemic preconditioning in vivo", CIRCULATION, vol. 106, 2002, pages 2881 - 2883 |
| KITAKAZE M; NODE K; MINAMINO T; KOMAMURA K; FUNAYA H; SHINOZAKI Y; CHUJO M; MORI H; INOUE M; HORI M: "Role of activation of protein kinase C in the infarct size-limiting effect of ischemic preconditioning through activation of ecto-5'-nucleotidase", CIRCULATION, vol. 93, 1996, pages 781 - 791 |
| KNAAPEN P; BOELLAARD R; GOTTE MJ; DIJKMANS PA; VAN CAMPEN LM; DE COCK CC; LUURTSEMA G; VISSER CA; LAMMERTSMA AA; VISSER FC: "Perfusable tissue index as a potential marker of fibrosis in patients with idiopathic dilated cardiomyopathy", J NUCL MED., vol. 45, 2004, pages 1299 - 1304 |
| KNAAPEN P; BOELLAARD R; GOTTE MJ; VAN DER WEERDT AP; VISSER CA; LAMMERTSMA AA; VISSER FC: "The perfusable tissue index: a marker of myocardial viability", J NUCL CARDIOL., vol. 10, 2003, pages 684 - 691 |
| KNAAPEN P; BONDARENKO O; BEEK AM; GOTTE MJ; BOELLAARD R; VAN DER WEERDT AP; VISSER CA; VAN ROSSUM AC; LAMMERTSMA AA; VISSER FC: "Impact of Scar on Water-Perfusable Tissue Index in Chronic Ischemic Heart Disease : Evaluation with PET and Contrast-Enhanced MRI", MOL IMAGING BIOL., 2006 |
| KNAAPEN P; VAN DOCKUM WG; BONDARENKO O; KOK WE; GOTTE MJ; BOELLAARD R; BEEK AM; VISSER CA; VAN ROSSUM AC; LAMMERTSMA AA: "Delayed contrast enhancement and perfusable tissue index in hypertrophic cardiomyopathy: comparison between cardiac MRI and PET", J NUCL MED., vol. 46, 2005, pages 923 - 929 |
| KNUUTI MJ; NUUTILA P; RUOTSALAINEN U; SARASTE M; HARKONEN R; AHONEN A; TERAS M; HAAPARANTA M; WEGELIUS U; HAAPANEN A: "Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography", J NUCL MED., vol. 33, 1992, pages 1255 - 1262 |
| KOMURO H.: "Junkanki Shikkan no Saisei Iryo", UEHARA MEMORIAL FOUNDATION KENKYU HOKOKU, vol. 17, 2003, pages 352 - 356, XP002999854 * |
| KRUM H; HAAS SJ; EICHHORN E; GHALI J; GILBERT E; LECHAT P; PACKER M; ROECKER E; VERKENNE P; WEDEL H: "Prognostic benefit of beta- blockers in patients not receiving ACE-Inhibitors", EUR HEART J., vol. 26, 2005, pages 2154 - 2158 |
| LIDA H; RHODES CG; DE SILVA R; ARAUJO LI; BLOOMFIELD PM; LAMMERTSMA AA; JONES T: "Use of the left ventricular time-activity curve as a noninvasive input function in dynamic oxygen-15-water positron emission tomography", J NUCL MED., vol. 33, 1992, pages 1669 - 1677 |
| LIDA H; RHODES CG; DE SILVA R; YAMAMOTO Y; ARAUJO LI; MASERI A; JONES T: "Myocardial tissue fraction--correction for partial volume effects and measure of tissue viability", J NUCL MED., vol. 32, 1991, pages 2169 - 2175 |
| LIDA H; TAKAHASHI A; TAMURA Y; ONO Y; LAMMERTSMA AA: "Myocardial blood flow: comparison of oxygen-15-water bolus injection, slow infusion and oxygen-15-carbon dioxide slow inhalation", J NUCL MED., vol. 36, 1995, pages 78 - 85 |
| LIDA H; TAMURA Y; KITAMURA K; BLOOMFIELD PM; EBERL S; ONO Y: "Histochemical correlates of (15)O-water-perfusable tissue fraction in experimental canine studies of old myocardial infarction", J NUCL MED., vol. 41, 2000, pages 1737 - 1745 |
| MILLARD RW: "Induction of functional coronary collaterals in the swine heart", BASIC RES CARDIOL., vol. 76, 1981, pages 468 - 473 |
| MILLS I; FALLON JT; WRENN D; SASKEN H; GRAY W; BIER J; LEVINE D; BERMAN S; GILSON M; GEWIRTZ H: "Adaptive responses of coronary circulation and myocardium to chronic reduction in perfusion pressure and flow", AM J PHYSIOL., vol. 266, 1994, pages H447 - 457 |
| MOSES MA; ADDISON PD; NELIGAN PC; ASHRAFPOUR H; HUANG N; MCALLISTER SE; LIPA JE; FORREST CR; PANG CY: "Inducing late phase of infarct protection in skeletal muscle by remote preconditioning: efficacy and mechanism", AM J PHYSIOL REGUL INTEGR COMP PHYSIOL., vol. 289, 2005, pages R1609 - 1617 |
| O'KONSKI MS; WHITE FC; LONGHURST J; ROTH D; BLOOR CM: "Ameroid constriction of the proximal left circumflex coronary artery in swine. A model of limited coronary collateral circulation", AM J CARDIOVASC PATHOL., vol. 1, 1987, pages 69 - 77 |
| ROTH DM; MARUOKA Y; ROGERS J; WHITE FC; LONGHURST JC; BLOOR CM: "Development of coronary collateral circulation in left circumflex Ameroid- occluded swine myocardium", AM J PHYSIOL., vol. 253, 1987, pages H1279 - 1288 |
| ROTH DM; WHITE FC; NICHOLS ML; DOBBS SL; LONGHURST JC; BLOOR CM: "Effect of long-term exercise on regional myocardial function and coronary collateral development after gradual coronary artery occlusion in pigs", CIRCULATION, vol. 82, 1990, pages 1778 - 1789 |
| SAITO 1; FOLSOM AR; AONO H; OZAWA H; IKEBE T; YAMASHITA T: "Comparison of fatal coronary heart disease occurrence based on population surveys in Japan and the USA", INT J EPIDEMIOL., vol. 29, 2000, pages 837 - 844 |
| See also references of EP1808071A4 * |
| SHEN YT; VATNER SF: "Mechanism of impaired myocardial function during progressive coronary stenosis in conscious pigs. Hibernation versus stunning", CIRC RES., vol. 76, 1995, pages 479 - 488 |
| YAMAMOTO Y; DE SILVA R; RHODES CG; ARAUJO LI; LIDA H; RECHAVIA E; NIHOYANNOPOULOS P; HACKETT D; GALASSI AR; TAYLOR CJ: "A new strategy for the assessment of viable myocardium and regional myocardial blood flow using 150-water and dynamic positron emission tomography", CIRCULATION, vol. 86, 1992, pages 167 - 178 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010150715A1 (ja) | 2009-06-26 | 2010-12-29 | 日本合成化学工業株式会社 | 心筋梗塞非ヒト動物モデル及びその作製方法 |
| JP2011004665A (ja) * | 2009-06-26 | 2011-01-13 | Nippon Synthetic Chem Ind Co Ltd:The | 心筋梗塞非ヒト動物モデル及びその作製方法 |
| JP2011097850A (ja) * | 2009-11-04 | 2011-05-19 | Terumo Corp | 心筋梗塞モデル動物の作製方法 |
| JP2017131158A (ja) * | 2016-01-28 | 2017-08-03 | 中島 博 | 心臓の肉眼観察可能なモデル動物及びその作製方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2006030737A1 (ja) | 2008-05-15 |
| JP4779122B2 (ja) | 2011-09-28 |
| US20080295189A1 (en) | 2008-11-27 |
| EP1808071A4 (en) | 2009-05-13 |
| EP1808071A1 (en) | 2007-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2758953B2 (ja) | 血小板依存性動脈血栓症の予防方法 | |
| Berent et al. | Portosystemic vascular anomalies | |
| Kikuchi et al. | Vascular malformations of the brain in hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber disease) | |
| CN110168077A (zh) | 用于治疗下肢外周动脉疾病的细胞悬液 | |
| JP5612279B2 (ja) | 心筋梗塞非ヒト動物モデル及びその作製方法 | |
| Krueger et al. | Protocol of a thromboembolic stroke model in the rat: review of the experimental procedure and comparison of models | |
| Pietilä et al. | Animal model for cerebral arteriovenous malformation | |
| Spradley et al. | Utero-placental vascular remodeling during late gestation in Sprague-Dawley rats | |
| JP4779122B2 (ja) | 動脈閉塞性疾病モデル動物の作製 | |
| CN109044555A (zh) | 介入法建立犬自体血栓栓塞性脑梗死溶栓后颅内出血转化模型及其应用 | |
| Kengelbach-Weigand et al. | Intra-and postoperative blood flow monitoring in a sheep model of uterus transplantation | |
| Knutsen et al. | Vascular casting of adult and early postnatal mouse lungs for micro-CT imaging | |
| Komatsu et al. | A novel rat model of embolic cerebral ischemia using a cell-implantable radiopaque hydrogel microfiber | |
| Ahmed et al. | The microglial TREM2 receptor programs hippocampal development in a mouse model of childhood deprivation | |
| Connery et al. | Cellophane banding of congenital intrahepatic portosystemic shunts in two Irish wolfhounds | |
| CN101056535A (zh) | 动脉闭塞性疾病动物模型的构建 | |
| Liu et al. | Construction of a canine model with acute type B aortic dissection using a self-made pressure-driven flow device | |
| JPH07196650A (ja) | 平滑筋細胞増殖抑制作用を有するアルガトロバン製剤 | |
| KR101474063B1 (ko) | 피브린 표적 펩타이드 서열이 결합된 글라이콜 키토산-금 나노입자를 포함하는 혈전 탐지용 ct 조영제 | |
| Cornelissen et al. | A study on the pathogenesis of equine sesamoiditis: The effects of experimental occlusion of the sesamoidean artery | |
| Gasparrini et al. | Repeated TACE in HCC after Fontan surgery and situs viscerum inversus: a case report | |
| JP2015057984A (ja) | 虚血モデル動物の作製法 | |
| Liu et al. | How to create a nervous system aneurysm model in canines? ligation of the lingual artery is a simple and effective method | |
| ES2445448T3 (es) | Composiciones y procedimientos de producción de oclusión vascular usando un agente de unión de plaquetas en fase sólida | |
| RU2811651C1 (ru) | Способ моделирования хронической тромбоэмболической легочной гипертензии у крупных животных |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2006535873 Country of ref document: JP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2005781914 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 200580038838.9 Country of ref document: CN |
|
| WWP | Wipo information: published in national office |
Ref document number: 2005781914 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 11662281 Country of ref document: US |